Special Issue

Innovative Prophylactic and Therapeutics for the Treatment of Coronavirus Infection

Message from the Guest Editors

While COVID-19 is no longer a pandemic, a significant number of SARS-CoV-2 infections still occur around the world due to emerging viral variants. Massive vaccine campaigns initiated in early 2021 have saved millions of lives. More recently, antivirals have been used to therapeutically control SARS-CoV-2 infections. However, because viral variants are continuously emerging, including those with mutations that can escape immune responses induced by approved vaccines or the antiviral activity of antivirals, new prophylactic and/or therapeutic approaches are urgently needed to assure SARS-CoV-2 infection remains controlled. The concern that a new coronavirus could surface is ever present, and the development of new prophylactics/therapeutics is crucial to safeguard against potential future coronavirus pandemics. In this Special issue, we welcome submissions of original research, reviews, clinical trials, and opinion articles related to new prophylactic and therapeutic interventions for the treatment of SARS-CoV-2 and other coronavirus infections.

Guest Editors

Prof. Dr. Luis Martinez-Sobrido

Disease Prevention and Intervention Program, Texas Biomedical Research Institute, San Antonio, TX, USA

Prof. Dr. Jun-Gyu Park

Laboratory of Veterinary Zoonotic Diseases, College of Veterinary Medicine, Chonnam National University, Gwangju, Republic of Korea

Deadline for manuscript submissions

31 August 2025



Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/226995

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/ viruses





Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAq, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).